Imatinib Aurovitas (Imatinib)

Imatinib blocks the ATP‑binding site of the BCR‑ABL fusion protein and other tyrosine kinases such as c‑KIT and PDGFR. This inhibition prevents phosphorylation of downstream targets, halting the signaling pathways that promote uncontrolled proliferation, survival, and migration of cancer cells, ultimately leading to apoptosis of cells reliant on these pathways.

The appropriate dose of Imatinib Aurovitas is determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Clinicians tailor the regimen to achieve optimal therapeutic effect while monitoring safety.

Imatinib is classified as a pregnancy‑category drug with potential risks to the fetus, and it is generally recommended to avoid use unless the potential benefit justifies the risk. Breastfeeding is also discouraged because the drug can be excreted in milk. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare provider.

To request Imatinib Aurovitas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for chronic myeloid leukemia and several other indications. Newer agents such as dasatinib and nilotinib have higher potency and may be used when resistance or intolerance to imatinib occurs. Choice of therapy depends on disease characteristics, mutation profile, side‑effect tolerance and physician experience.

Imatinib Aurovitas tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity, which could compromise tablet integrity.

Imatinib Aurovitas is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations to maintain consistent absorption.

The most serious adverse events include severe neutropenia or other cytopenias, hepatotoxicity manifested by elevated liver enzymes or liver injury, and cardiac failure or reduced left‑ventricular function. Patients should be monitored regularly for blood counts, liver function, and cardiac status, and any new symptoms such as fever, jaundice, or shortness of breath should be reported promptly.

Imatinib Aurovitas is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks. Physicians should evaluate each patient’s medical history before initiating therapy.